Speaker Profile

M.D., Ph.D., Clinical Geneticist, Head of Clinical Studies and Medical Information, Invitae

Dr. Esplin is board-certified in clinical genetics and internal medicine. Prior to joining Invitae, he practiced clinical genetics at Kaiser Permanente's San Francisco Medical Center. Dr. Esplin completed the medical scientist training program at the University of Texas Southwestern completing his M.D. with a Ph.D. in genetics (emphasis in cancer genetics). After his internal medicine residency at UT Southwestern, he was appointed assistant professor of the University of Texas Southwestern Department of Internal Medicine. Dr. Esplin completed his clinical fellowship training in medical genetics and postdoctoral fellowship in genetics and genomics under Mike Snyder at Stanford, during which time he was supported by an award from the Tashia and John Morgridge Endowed Postdoctoral Fellowship program and by the National Institutes of Health-funded Stanford Clinical and Translational Science Award.

Clinical Dx Showcase:

Invitae’s mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people.

Precision Therapy Through Combined Germline And Tumor Genetic Testing
Germline genetic testing combined with somatic tumor sequencing identifies precision therapies and clinical trials for patients with cancer that would be missed by tumor-only sequencing.

 Session Abstract – PMWC 2020 Silicon Valley

Track 6 - January 22 2.30 P.M.-3.45 P.M.,Track 7 - January 23 1.15 P.M.-1.30 P.M.,Track 6 - January 24 9.00 A.M.-1.15 P.M.

The PMWC 2020 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.